tiprankstipranks
Avicanna Reports Strong Growth and Medical Trials Success
Company Announcements

Avicanna Reports Strong Growth and Medical Trials Success

Story Highlights

Avicanna (TSE:AVCN) has released an update.

Don't Miss Our Christmas Offers:

Avicanna Inc. has reported a significant revenue increase of 85% in Q2 2024, reaching $6.1 million, while also announcing the successful completion of two real-world evidence trials for medical cannabis products aimed at treating Epidermolysis Bullosa and Musculoskeletal Pain. The company highlighted a steady growth in their financial performance and advancements in their medical research, strengthening their position in the medical cannabis industry.

For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAvicanna Expands with First European Product Delivery
TheFlyAvicanna completes first delivery of topical products to pharmaceutical company
TipRanks Auto-Generated NewsdeskAvicanna Inc. Reports Strong Growth in Q3 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App